All Title Author
Keywords Abstract

PLOS ONE  2013 

Carboplatin +/? Topotecan Ophthalmic Artery Chemosurgery for Intraocular Retinoblastoma

DOI: 10.1371/journal.pone.0072441

Full-Text   Cite this paper   Add to My Lib


Purpose Carboplatin administered systemically or periocularly can result in dramatic and prompt regression of retinoblastoma. However, both routes are rarely curative alone and have undesirable side effects. We aimed to assess the efficacy and toxicity of carboplatin +/? topotecan delivered by ophthalmic artery chemosurgery whereby chemotherapy is infused into the eye via the ophthalmic artery. Methods This retrospective, IRB-approved study investigated retinoblastoma patients whom received carboplatin +/? topotecan ophthalmic artery chemosurgery. Patient survival, ocular survival, hematologic toxicity, ocular toxicity, second cancer development and electroretinogram response were all evaluated. Results 57 carboplatin +/? topotecan infusions (of 111 total) were performed in 31 eyes of 24 patients. The remaining infusions were melphalan-containing. All patients were alive and no patient developed a second malignancy at a median follow up of 25 months. The Kaplan-Meier estimate of ocular survival at two years was 89.9% (95% confidence interval [CI], 82.1–97.9%) for all eyes. Grade 3 or 4 neutropenia developed in two patients and one patient developed metastatic disease. By univariate analysis, neither increasing maximum carboplatin/topotecan dose nor cumulative carboplatin/topotecan dose was associated with statistically significant reduction in the electroretinogram responses. Conclusion Carboplatin +/? topotecan infusions are effective for ophthalmic artery chemosurgery in retinoblastoma: they demonstrate low hematologic and ocular toxicity and no statistically significant influence on electroretinogram responses, and used in conjunction with melphalan-containing OAC, demonstrate excellent patient survival and satisfactory ocular survival.


[1]  Abramson DH, Ellsworth RM, Zimmerman LE (1976) Nonocular cancer in retinoblastoma survivors. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol 81: 454–7.
[2]  Eng C, Li FP, Abramson DH, Ellsworth RM, Wong FL, et al. (1993) Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 85: 1121–8.
[3]  Abramson DH, Frank CM (1998) Second nonocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. Ophthalmology 105: 573–80.
[4]  Marees T, Moll AC, Imhof SM, de Boer MR, Ringens PJ, et al. (2008) Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst 100: 1771–9.
[5]  Kupfer C (1953) Retinoblastoma treated with intravenous nitrogen mustard. Am J Ophthalmol 36: 1721–3.
[6]  Doz F, Neuenschwander S, Plantaz D, Courbon B, Gentet JC, et al. (1995) Etoposide and carboplatin in extraocular retinoblastoma: a study by the Société Fran?aise d’Oncologie Pédiatrique. J Clin Oncol 13 902–9.
[7]  Murphree AL, Villablanca JG, Deegan WF, Sato JK, Malogolowkin, et al (1996) Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 114: 1348–56.
[8]  Dunkel IJ, Lee TC, Shi W, Beaverson KL, Novetsky D, et al. (2007) A phase II trial of carboplatin for intraocular retinoblastoma. Pediatr Blood Cancer 49: 643–8.
[9]  Abramson DH, Lawrence SD, Beaverson KL, Lee TC, Rollins IS, et al. (2005) Systemic carboplatin for retinoblastoma: change in tumour size over time. Br J Ophthalmol 89: 1616–9.
[10]  Abramson DH, Frank CM, Dunkel IJ (1999) A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology 106: 1947–50.
[11]  Reese AB, Hyman GA, Merriam GR, Forrest AW, Kligermann MM (1954) Treatment of retinoblastoma by radiation and triethylenemelamine. AMA Arch Ophthalmol 153: 505–13.
[12]  Yamane T, Kaneko A, Mohri M (2004) The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol 9: 69–73.
[13]  Inomata M, Kaneko A (1987) Chemosensitivity profiles of primary and cultured human retinoblastoma cells in a human tumor clonogenic assay. Jpn J Cancer Res 78: 858–68.
[14]  Suzuki S, Yamane T, Mohri M, Kaneko A (2011) Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology 118: 2081–7.
[15]  Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP (2008) A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology 115: 1398–1404.
[16]  Abramson DH (2011) Chemosurgery for retinoblastoma: what we know after 5 years. Arch Ophthalmol 129: 1492–4.
[17]  Gobin YP, Dunkel IJ, Marr BP, Brodie SE, Abramson DH (2011) Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol 129: 732–7.
[18]  Brodie SE, Gobin YP, Dunkel IJ, Kim JW, Abramson DH (2009) Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma. Doc Ophthalmol 119: 13–22.
[19]  Francis JH, Gobin YP, Brodie SE, Marr BP, Dunkel IJ, Abramson DH (2012) Experience of intra-arterial chemosurgery with single agent carboplatin for retinoblastoma. Br J Ophthalmol.
[20]  Francis JH, Gobin YP, Nagiel A, Dunkel IJ, Kucine N, et al. (2012) Thrombophilia in patients with retinoblastoma receiving ophthalmic artery chemosurgery. Arch Ophthalmol 130: 1605–8.
[21]  Gobin YP, Dunkel IJ, Marr BP, Francis JH, Brodie SE, et al. (2012) Combined, sequential intravenous and intra-arterial chemotherapy (bridge chemotherapy) for young infants with retinoblastoma. PLoS ONE 7: e44322.
[22]  Graeber CP, Gobin YP, Marr BP, Dunkel IJ, Brodie SE, et al. (2011) Histopathologic findings of eyes enucleated after treatment with chemosurgery for retinoblastoma. Open Ophthalmol J 5: 1–5.
[23]  Klufas MA, Gobin YP, Marr B, Brodie SE, Dunkel IJ, et al.. (2012) Intra-Arterial Chemotherapy as a Treatment for Intraocular Retinoblastoma: Alternatives to Direct Ophthalmic Artery Catheterization. AJNR Am J Neuroradiol.
[24]  Marr BP, Brodie SE, Dunkel IJ, Gobin YP, Abramson DH (2012) Three-drug intra-arterial chemotherapy using simultaneous carboplatin, topotecan, and melphalan for intraocular retinoblastoma: preliminary results. Br J Ophthalmol.
[25]  Palioura S, Gobin YP, Brodie SE, Marr BP, Dunkel IJ, et al.. (2012) Ophthalmic artery chemosurgery for the management of retinoblastoma in eyes with extensive (>50%) retinal detachment. Pediatr Blood Cancer.
[26]  Marr B, Gobin PY, Dunkel IJ, Brodie SE, Abramson DH (2010) Spontaneously Resolving Periocular Erythema and Ciliary Madarosis Following Intra-arterial Chemotherapy for Retinoblastoma. Middle East Afr J Ophthalmol 17: 207–9.
[27]  Calvaruso G, Carabillò M, Giuliano M, Lauricella M, D’Anneo A, et al. (2001) Sodium phenylbutyrate induces apoptosis in human retinoblastoma Y79 cells: the effect of combined treatment with the topoisomerase I-inhibitor topotecan. Int. J. Oncol. 18: 1233–7.
[28]  Laurie NA, Gray JK, Zhang J, Leggas M, Relling M, et al. (2005) Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clin. Cancer Res. 11: 7569–78.
[29]  Chantada GL, Fandino AC, Casak SJ, Mato G, Manzitti J, et al. (2004) Activity of topotecan in retinoblastoma. Ophthalmic Genet. 25: 37–43.
[30]  Schefler AC, Abramson DH (2008) Retinoblastoma: what is new in 2007–2008. Curr Opin Ophthalmol 19: 526–34.
[31]  Abramson DH, Lawrence SD, Beaverson KL, Lee TC, Rollins IS, et al. (2005) Systemic carboplatin for retinoblastoma: change in tumor size over time. Br J Ophthalmol 89: 1616–1619.
[32]  Wilson MW, Rodriguez-Galindo C, Haik BG, Moshfeghi DM, Merchant TE, et al. (2001) Multiagent chemotherapy as neoadjuvant treatment for multifocal intraocular retinoblastoma. Ophthalmology 108: 2106–15.
[33]  Shields CL, De Potter P, Himelstein BP, Shields JA, Meadows AT, et al. (1996) Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol 114: 1330–8.
[34]  Gallie BL, Budning A, DeBoer G, Thiessen JJ, Koren G, et al. (1996) Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 114: 1321–8.
[35]  Benz MS, Scott IU, Murray TG, Kramer D, Toledano S (2000) Complications of systemic chemotherapy as treatment of retinoblastoma. Arch Ophthalmol 118: 577–8.
[36]  Pecora Liberman PH, Schultz C, Schmidt Goffi-Gómez MV, Antoneli CBG, Motoro Chojniak M, et al. (2011) Evaluation of ototoxicity in children treated for retinoblastoma: preliminary results of a systematic audiological evaluation. Clin Transl Oncol 13: 348–52.
[37]  Shearer P (2009) Carboplatin ototoxicity in retinoblastoma: Onset and monitoring. Pediatr Blood Cancer 53: 517–7.
[38]  Qaddoumi I, Bass JK, Wu J, Billups CA, Wozniak AW, et al. (2012) Carboplatin-Associated Ototoxicity in Children With Retinoblastoma. J Clin Oncol 30: 1034–41.
[39]  Gombos DS, Hungerford J, Abramson DH, Kingston J, Chantada G, et al. (2007) Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology 114: 1378–83.
[40]  Jeruss JS, Woodruff TK (2009) Preservation of fertility in patients with cancer. N Engl J Med 360: 902–911.
[41]  Suzuki S, Kaneko A (2004) Management of intraocular retinoblastoma and ocular prognosis. Int J Clin Oncol 9: 1e6.
[42]  Gombos DS, Cauchi PA, Hungerford JL, Addison P, Coen PG, et al. (2006) Vitreous relapse following primary chemotherapy for retinoblastoma: is adjuvant diode laser a risk factor? Br J Ophthalmol 90: 1168–72.
[43]  Kim JH, Yu YS, Khwarg SI, Choi HS, Shin HY, et al. (2003) Clinical result of prolonged primary chemotherapy in retinoblastoma patients. Korean J Ophthalmol 17: 35–43.
[44]  Mendelsohn ME, Abramson DH, Madden T, Tong W, Tran HT, et al. (1998) Intraocular concentrations of chemotherapeutic agents after systemic or local administration. Arch Ophthalmol 116: 1209–1212.
[45]  Mulvihill A, Budning A, Jay V, Vandenhoven C, Heon E, et al. (2003) Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol 121: 1120–1124.
[46]  Schmack I, Hubbard GB, Kang SJ, Aaberg TM Jr, Grossniklaus HE (2006) Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma. Am J Ophthalmol 142: 310–315.
[47]  Abramson DH, Dunkel IJ, Brodie SE, Marr B, Gobin YP (2010) Bilateral superselective ophthalmic artery chemotherapy for bilateral retinoblastoma: tandem therapy. Arch Ophthalmol 128: 370–2.
[48]  Schaiquevich P, Buitrago E, Taich P, Torbidoni A, Ceciliano A, et al. (2012) Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinical models and retinoblastoma patients. Invest Ophthalmol Vis Sci 53: 4205–12.
[49]  Pratt CB, Stewart C, Santana VM, Bowman L, Furman W, et al. (1994) Phase I study of topotecan for pediatric patients with malignant solid tumors. J. Clin. Oncol. 12: 539–43.
[50]  Van Quill KR, Dioguardi PK, Tong CT, Gilbert JA, Aaberg TM, et al. (2005) Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma. Ophthalmology 112: 1151–1158.
[51]  Zlioba A, Peyman GA, Nikoleit J (1988) Retinal toxicity study of intravitreal carboplatin and iproplatin. Ann Ophthalmol 20: 71–2.
[52]  Harbour JW, Murray TG, Hamasaki D, Cicciarelli N, Hernandez E, et al. (1996) Local carboplatin therapy in trans- genic murine retinoblastoma. Invest Ophthalmol Vis Sci 37: 1892–98.
[53]  Pardue MT, Hejny C, Gilbert JA, Phillips MJ, Geroski DH, et al. (2004) Retinal function after subconjunctival injection of carboplatin in fibrin sealant. Retina 24: 776–82.
[54]  Stewart DJ, Belanger JM, Grahovac Z, Curuvija S, Gionet LR, et al. (1992) Phase I study of intracarotid administration of carboplatin. Neurosurgery 30: 512–7.


comments powered by Disqus